Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion.
作者： Sophie E. McGrath , Andrew Webb , Karen Walker-Bone
关键词: Iloprost 、 Multimodal imaging 、 X ray computed 、 Positron emission tomography 、 Surgery 、 Radiology 、 Remission induction 、 Medicine 、 Bleomycin 、 Treatment outcome
摘要:
sci-hub.se 参考文章(10)
Janet Pope, D Fenlon, A Thompson, Beverley Shea, Dan Furst, George A Wells, Alan Silman, Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis Cochrane Database of Systematic Reviews. ,(1998) , 10.1002/14651858.CD000953
JCR Bowling, PM Dowd, Raynaud's disease. The Lancet. ,vol. 361, pp. 2078- 2080 ,(2003) , 10.1016/S0140-6736(03)13646-X
Sven Gottschling, Sascha Meyer, Harald Reinhard, Thomas Krenn, Norbert Graf, First report of a vincristine dose-related Raynaud's phenomenon in an adolescent with malignant brain tumor. Journal of Pediatric Hematology Oncology. ,vol. 26, pp. 768- 769 ,(2004) , 10.1097/00043426-200411000-00017
C.C. Berger, C. Bokemeyer, M. Schneider, M.A. Kuczyk, H.-J. Schmoll, Secondary Raynaud's Phenomenon and Other Late Vascular Complications Following Chemotherapy for Testicular Cancer European Journal of Cancer. ,vol. 31, pp. 2229- 2238 ,(1995) , 10.1016/0959-8049(95)00460-2
Jennifer L Glendenning, Yolanda Barbachano, Andy R. Norman, David P. Dearnaley, Alan Horwich, Robert A. Huddart, Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. ,vol. 116, pp. 2322- 2331 ,(2010) , 10.1002/CNCR.24981
Sophie D. Fosså, Gustav Lehne, Ketil Heimdal, Liv Theodorsen, Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology. ,vol. 52, pp. 300- 305 ,(1995) , 10.1159/000227478
J�rg Thomas Hartmann, Christian Kollmannsberger, Lothar Kanz, Carsten Bokemeyer, Platinum organ toxicity and possible prevention in patients with testicular cancer. International Journal of Cancer. ,vol. 83, pp. 866- 869 ,(1999) , 10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9
Alfonso J De LaVega, Chris T Derk, Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opinion on Investigational Drugs. ,vol. 18, pp. 23- 29 ,(2009) , 10.1517/13543780802525100
O Kowal-Bielecka, R Landewé, J Avouac, S Chwiesko, I Miniati, L Czirjak, P Clements, C Denton, D Farge, K Fligelstone, I Földvari, D E Furst, U Müller-Ladner, J Seibold, R M Silver, K Takehara, B Garay Toth, A Tyndall, G Valentini, F van den Hoogen, F Wigley, F Zulian, Marco Matucci-Cerinic, , EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Annals of the Rheumatic Diseases. ,vol. 68, pp. 620- 628 ,(2009) , 10.1136/ARD.2008.096677
S W Hansen, N Olsen, Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. Journal of Clinical Oncology. ,vol. 7, pp. 940- 942 ,(1989) , 10.1200/JCO.1989.7.7.940